<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>clinical risk assessment &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/clinical-risk-assessment/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 26 Oct 2026 22:34:06 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>clinical risk assessment &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Weight normalization keeps interval type-2 fuzzy uncertainty bounded</title>
		<link>https://bioengineer.org/weight-normalization-keeps-interval-type-2-fuzzy-uncertainty-bounded/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Mon, 26 Oct 2026 22:34:06 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[Algebraic]]></category>
		<category><![CDATA[autoregressive inputs]]></category>
		<category><![CDATA[clinical risk assessment]]></category>
		<category><![CDATA[fuzzy aggregation]]></category>
		<category><![CDATA[industrial fault detection]]></category>
		<category><![CDATA[interval type-2 fuzzy sets]]></category>
		<category><![CDATA[Mamdani inference]]></category>
		<category><![CDATA[multi-criteria decision-making]]></category>
		<category><![CDATA[uncertainty quantification]]></category>
		<category><![CDATA[weight normalization]]></category>
		<category><![CDATA[width]]></category>
		<category><![CDATA[width certificates]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=457195</guid>

					<description><![CDATA[A theoretical and computational study identifies normalized weights as the condition that keeps interval type-2 fuzzy aggregation uncertainty bounded as decision criteria accumulate.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">457195</post-id>	</item>
		<item>
		<title>Genetic and metabolic risks linked to early cirrhosis in adults with MASLD</title>
		<link>https://bioengineer.org/genetic-and-metabolic-risks-linked-to-early-cirrhosis-in-adults-with-masld/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Mon, 26 Oct 2026 22:27:17 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[adults]]></category>
		<category><![CDATA[clinical risk assessment]]></category>
		<category><![CDATA[early-onset cirrhosis]]></category>
		<category><![CDATA[fibrosis screening]]></category>
		<category><![CDATA[finds]]></category>
		<category><![CDATA[Genetic Susceptibility]]></category>
		<category><![CDATA[Hepatocellular Carcinoma]]></category>
		<category><![CDATA[Liver Fibrosis]]></category>
		<category><![CDATA[MASLD]]></category>
		<category><![CDATA[obesity]]></category>
		<category><![CDATA[Type 2 diabetes]]></category>
		<category><![CDATA[Young]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=457066</guid>

					<description><![CDATA[An analysis of about 2,400 adults with biopsy-confirmed MASLD linked early-onset cirrhosis to genetic susceptibility and type 2 diabetes, while standard fibrosis scores would not prompt further evaluation in nearly one-third of affected younger patients.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">457066</post-id>	</item>
	</channel>
</rss>
